X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Active, not recruiting · NCT03753685 · Registry updated 2025-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | Brain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03753685 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Betta Pharmaceuticals Co., Ltd. | 20 |
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center | Shenzhen | China | 2 |